Stock info Sinovac Biotech | Filter  Basic-Info

Sinovac Biotech

The past year was a good year for Sinovac Biotech investors

Over the last 12 months, that were profitable period for the investors in Sinovac Biotech, the stock gained around 11 percent. Sinovac Biotech' stock rose the past 5 years at around 171 percent. Sinovac Biotech's revenues between 2011 and 2015 were very volatile and moved between 49,22 million dollars and 67,41 million dollars. Sinovac Biotech's net results between 2011 and 2015 were quite unstable and moved between -0,4 million dollars and 0,52 million dollars.

Sinovac Biotech primarily operates in the pharmaceutical sector. The global pharmaceutical companies gained around 75 percent over the last 10 years. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-2016) there is a minus of 75 percent.

The American company didn't pay out any dividends (in the past 5 years).

Healthy financed: not so much debt Sinovac Biotech

At the end of 2015 the American company had a balance sheet of around 202,98 million dollars. 79,7 million dollars (39,26 percent of the total balance sheet) was financed by debt. As per the end of 2015 Sinovac Biotech's price/earnings-ratio equaled -523. So investors paid for 1 stock -523 times the earnings per share of 2015. Based on it's price/earnings-ratio and dividend yield the American stock can be seen as a growth stock.

At the end of 2015 the American company's market capitalization equaled around 316,97 million dollars. At the end of 2015 the American company had around 56,91 million stocks listed on the exchanges.

On this page you can find all Sinovac Biotech's financial reports. More information about Sinovac Biotech can be found it's website. .